Menu
1 min read · estimated
APPROVED USE
What FDA approved
Interchangeable Xgeva biosimilar for prevention of skeletal events in multiple myeloma and bone metastases from solid tumors; for adults and skeletally mature adolescents with giant cell tumor of bone when surgery is unsuitable or would cause severe morbidity; and for hypercalcemia of malignancy refractory to bisphosphonates.
LAMPGEN ANALYSIS
Why it matters
The FDA licensed an interchangeable denosumab product for cancer-related skeletal complications and other labeled oncology settings.
What research teams should watch
Avoid mixing the cancer and bone-loss product strengths; track calcium, dental assessment and the specific treatment indication.
PRIMARY RECORDS